<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00691717</url>
  </required_header>
  <id_info>
    <org_study_id>C-07-36</org_study_id>
    <nct_id>NCT00691717</nct_id>
  </id_info>
  <brief_title>Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety and intraocular-lowering efficacy of
      anecortave acetate depot when administered by anterior juxtascleral depot (AJD) for the
      treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or
      ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Intraocular Pressure at 8 am</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Who Remained Rescue Medication-Free at Month 3 (8 am)</measure>
    <time_frame>Month 3, 8 am</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Oular Hypertension</condition>
  <arm_group>
    <arm_group_label>24 mg Anecortave Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anecortave Acetate Sterile Suspension, 30 mg/mL, single depot administration of 0.8 mL in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48 mg Anecortave Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anecortave Acetate Sterile Suspension, 60 mg/mL, single depot administration of 0.8 mL in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg Anecortave Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anecortave Acetate Sterile Suspension, 75 mg/mL, single depot administration of 0.8 mL in the study eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anecortave Acetate Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single depot administration of 0.8 mL in the study eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Sterile Suspension, 30 mg/mL</intervention_name>
    <description>Single administration by anterior juxtascleral depot</description>
    <arm_group_label>24 mg Anecortave Acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Sterile Suspension, 60 mg/mL</intervention_name>
    <description>Single administration by anterior juxtascleral depot</description>
    <arm_group_label>48 mg Anecortave Acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anecortave Acetate Sterile Suspension, 75 mg/mL</intervention_name>
    <description>Single administration by anterior juxtascleral depot</description>
    <arm_group_label>60 mg Anecortave Acetate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anecortave Acetate Vehicle</intervention_name>
    <description>Single administration by anterior juxtascleral depot</description>
    <arm_group_label>Anecortave Acetate Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age or older with open-angle glaucoma (with or without pigment
             dispersion or pseudoexfoliation) or ocular hypertension.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Patients with any form of glaucoma other than open-angle.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charleston</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <disposition_first_submitted>November 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 28, 2012</disposition_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anecortave acetate</keyword>
  <keyword>Open-angle glaucoma</keyword>
  <keyword>IOP</keyword>
  <keyword>OHT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anecortave</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

